Immunogenicity of a recombinant envelope domain III protein of dengue virus type-4 with various adjuvants in mice.

[1]  F. Smithies.  Protozoiasis occurring in Temperate Zone Residents. A Study of 265 Instances with a Discussion of the Associated Digestive Malfunction. , 1926 .

[2]  A. Nisalak,et al.  A plaque reduction test for dengue virus neutralizing antibodies. , 1967, Journal of immunology.

[3]  R. Coffman,et al.  TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. , 1989, Annual review of immunology.

[4]  J L Grun,et al.  Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: the role of endogenous interleukin 1 in proliferative responses. , 1989, Cellular immunology.

[5]  C. Hackett,et al.  Dengue-1 virus envelope glycoprotein gene expressed in recombinant baculovirus elicits virus-neutralizing antibody in mice and protects them from virus challenge. , 1991, The American journal of tropical medicine and hygiene.

[6]  J. Schlesinger,et al.  Use of recombinant fusion proteins and monoclonal antibodies to define linear and discontinuous antigenic sites on the dengue virus envelope glycoprotein. , 1992, Virology.

[7]  R. Zinkernagel,et al.  Immune response in mice that lack the interferon-gamma receptor. , 1993, Science.

[8]  V. Deubel,et al.  Analysis of C-terminally truncated dengue 2 and dengue 3 virus envelope glycoproteins: processing in insect cells and immunogenic properties in mice. , 1994, The Journal of general virology.

[9]  E. Paoletti,et al.  Recombinant vaccinia viruses co-expressing dengue-1 glycoproteins prM and E induce neutralizing antibodies in mice. , 1994, Vaccine.

[10]  R. Warren,et al.  Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection. , 1995, Vaccine.

[11]  L. Borish,et al.  Update on cytokines. , 1996, The Journal of allergy and clinical immunology.

[12]  J. Clément,et al.  Dengue virus envelope glycoprotein can be secreted from insect cells as a fusion with the maltose-binding protein. , 1996, Journal of virological methods.

[13]  J. Sadoff,et al.  Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys. , 1996, The Journal of infectious diseases.

[14]  H. Bluethmann,et al.  In interleukin‐4‐deficient mice, alum not only generates T helper 1 responses equivalent to Freund's complete adjuvant, but continues to induce T helper 2 cytokine production , 1996, European journal of immunology.

[15]  R. Anders,et al.  Selection of an adjuvant for vaccination with the malaria antigen, MSA-2. , 1997, Vaccine.

[16]  V. Deubel,et al.  Affinity-purified dengue-2 virus envelope glycoprotein induces neutralizing antibodies and protective immunity in mice. , 1997, Vaccine.

[17]  J. Cox,et al.  Adjuvants--a classification and review of their modes of action. , 1997, Vaccine.

[18]  J. Esko,et al.  Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate , 1997, Nature Medicine.

[19]  Duane J. Gubler,et al.  Dengue and Dengue Hemorrhagic Fever , 1998, Clinical Microbiology Reviews.

[20]  C. Hayes,et al.  Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice. , 1998, The American journal of tropical medicine and hygiene.

[21]  S. J. Flint,et al.  Principles of Virology: Molecular Biology, Pathogenesis, and Control , 1999 .

[22]  B. Williams,et al.  Interferon action in triply deficient mice reveals the existence of alternative antiviral pathways. , 1999, Virology.

[23]  S. Assad,et al.  Over a decade of experience with a yeast recombinant hepatitis B vaccine. , 1999, Vaccine.

[24]  C. Hunter,et al.  Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. , 1999, Journal of immunology.

[25]  N. Sonenberg,et al.  The Murine Double-Stranded RNA-Dependent Protein Kinase PKR Is Required for Resistance to Vesicular Stomatitis Virus , 2000, Journal of Virology.

[26]  B. Moss,et al.  Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge. , 2000, Vaccine.

[27]  J. J. Greene,et al.  Purified dengue 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice. , 2000, Vaccine.

[28]  E. Holmes,et al.  The causes and consequences of genetic variation in dengue virus. , 2000, Trends in microbiology.

[29]  K. Russell,et al.  A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys. , 2000, Vaccine.

[30]  G. Murphy,et al.  Short report: Antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine. , 2001, The American journal of tropical medicine and hygiene.

[31]  K. Porter,et al.  Synergistic neutralizing antibody response to a dengue virus type 2 DNA vaccine by incorporation of lysosome-associated membrane protein sequences and use of plasmid expressing GM-CSF. , 2001, Virology.

[32]  F. Guirakhoo,et al.  Construction, Safety, and Immunogenicity in Nonhuman Primates of a Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine , 2001, Journal of Virology.

[33]  J. Roehrig,et al.  Monoclonal Antibodies That Bind to Domain III of Dengue Virus E Glycoprotein Are the Most Efficient Blockers of Virus Adsorption to Vero Cells , 2001, Journal of Virology.

[34]  W. Leitner,et al.  Designing immune responses with genetic immunization and immunostimulatory DNA sequences. , 2001, Endocrine Regulations.

[35]  S. Watowich,et al.  Biophysical Characterization and Vector-Specific Antagonist Activity of Domain III of the Tick-Borne Flavivirus Envelope Protein , 2001, Journal of Virology.

[36]  H. Bedouelle,et al.  Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralization mechanism. , 2001, The Journal of general virology.

[37]  F. Guirakhoo,et al.  Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. , 2002, Virology.

[38]  D. Gubler.  Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. , 2002, Trends in microbiology.

[39]  R. Putnak,et al.  Formalin-inactivated whole virus and recombinant subunit flavivirus vaccines. , 2003, Advances in virus research.

[40]  B. Innis,et al.  Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command. , 2003, The American journal of tropical medicine and hygiene.

[41]  R. Edelman,et al.  Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. , 2003, The American journal of tropical medicine and hygiene.

[42]  Y. Modis,et al.  A ligand-binding pocket in the dengue virus envelope glycoprotein , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[43]  C. Huang,et al.  Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development , 2003, Journal of Virology.

[44]  S. Halstead,et al.  Neutralization and antibody-dependent enhancement of dengue viruses. , 2003, Advances in virus research.

[45]  J. Lang,et al.  Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children , 2004, The Pediatric infectious disease journal.

[46]  Wen Chang,et al.  An External Loop Region of Domain III of Dengue Virus Type 2 Envelope Protein Is Involved in Serotype-Specific Binding to Mosquito but Not Mammalian Cells , 2004, Journal of Virology.

[47]  G. Chinea,et al.  A dengue-2 Envelope fragment inserted within the structure of the P64k meningococcal protein carrier enables a functional immune response against the virus in mice. , 2004, Journal of virological methods.

[48]  B. Murphy,et al.  Genetically modified, live attenuated dengue virus type 3 vaccine candidates. , 2004, The American journal of tropical medicine and hygiene.

[49]  B. Guy,et al.  Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine. , 2004, Vaccine.

[50]  D. Vaughn,et al.  An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. , 2005, Vaccine.

[51]  C. Ramos,et al.  Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein. , 2005, Vaccine.

[52]  F. Ennis,et al.  Dengue virus infection of human skin fibroblasts in vitro production of IFN-β, IL-6 and GM-CSF , 2005, Archives of Virology.

[53]  A. Barrett,et al.  Review on flavivirus vaccine development. Proceedings of a meeting jointly organised by the World Health Organization and the Thai Ministry of Public Health, 26-27 April 2004, Bangkok, Thailand. , 2005, Vaccine.

[54]  A. Rothman,et al.  Altered Cytokine Responses of Dengue-Specific CD4+ T Cells to Heterologous Serotypes 1 , 2005, The Journal of Immunology.

[55]  R. Karron,et al.  rDEN4Δ30, a Live Attenuated Dengue Virus Type 4 Vaccine Candidate, Is Safe, Immunogenic, and Highly Infectious in Healthy Adult Volunteers , 2005 .

[56]  S. Leppla,et al.  Plant-Based Vaccine: Mice Immunized with Chloroplast-Derived Anthrax Protective Antigen Survive Anthrax Lethal Toxin Challenge , 2005, Infection and Immunity.

[57]  [Effect of IL-6 and TNF-alpha on Dengue virus infection of human dendritic cells]. , 2006, Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology.

[58]  D. Burke,et al.  Antibody-dependent enhancement in dengue virus infections. , 2006, The Journal of infectious diseases.

[59]  M. Guzmán,et al.  A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. , 2006, Vaccine.

[60]  E. Konishi,et al.  Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice. , 2006, Vaccine.

[61]  S. Swaminathan,et al.  Induction of neutralizing antibodies specific to dengue virus serotypes 2 and 4 by a bivalent antigen composed of linked envelope domains III of these two serotypes. , 2006, The American journal of tropical medicine and hygiene.

[62]  J. Chin,et al.  The envelope glycoprotein domain III of dengue virus serotypes 1 and 2 inhibit virus entry. , 2007, Microbes and infection.

[63]  K. Musiychuk,et al.  Immunogenicity of a subunit vaccine against Bacillus anthracis. , 2007, Vaccine.

[64]  Virander S. Chauhan,et al.  Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice. , 2007, Vaccine.

[65]  Yan-sheng Yan,et al.  High-level expression of recombinant dengue virus type 2 envelope domain III protein and induction of neutralizing antibodies in BALB/C mice. , 2007, Journal of virological methods.

[66]  S. Swaminathan,et al.  An adenovirus prime/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes , 2007, BMC biotechnology.

[67]  J. Babu,et al.  Bacterially expressed and refolded envelope protein (domain III) of dengue virus type-4 binds heparan sulfate. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.